Drugs /

autologous ny-eso-1-specific cd8-positive t lymphocytes

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of autologous CD8+ T-lymphocytes specifically reactive to the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Autologous NY-ESO-1-specific CD8+ T-lymphocytes were generated from T-cells isolated from a particular cancer patient, which were made specifically reactive to the NY-ESO-1 antigen, expanded ex vivo, and reintroduced into the patient. These tumor-reactive T-cells may stimulate a host immune response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, may be upregulated in various cancers.

Clinical Trials

View Clinical Trials for autologous ny-eso-1-specific cd8-positive t lymphocytes

Autologous ny-eso-1-specific cd8-positive t lymphocytes has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating autologous ny-eso-1-specific cd8-positive t lymphocytes, 2 are phase 1 (2 open).

CTAG1A Expression, CTAG1B Expression, and HLA-A*02:01 Positive are the most frequent biomarker inclusion criteria for autologous ny-eso-1-specific cd8-positive t lymphocytes clinical trials.

Fallopian tube carcinoma, myxoid liposarcoma, and ovarian carcinoma are the most common diseases being investigated in autologous ny-eso-1-specific cd8-positive t lymphocytes clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Autologous Ny-Eso-1-Specific Cd8-Positive T Lymphocytes
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating autologous ny-eso-1-specific cd8-positive t lymphocytes and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous ny-eso-1-specific cd8-positive t cells, autologous ny-eso-1-specific cd8-positive t lymphocytes
Drug Target(s) [2]:
CTAG1B
NCIT ID [1]:
C118790

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.